瑞舒伐他汀对心脏舒张功能不全并运动高血压患者的影响

Impact of Rosuvastatin on Diastolic Cardiac Dysfunction Patients Complicated with Exercise Hypertension

目的探讨瑞舒伐他汀对心脏舒张功能不全并运动高血压患者的影响。方法选取2015年1月—2017年1月佛山市高明人民医院心内科收治的心脏舒张功能不全并运动高血压患者148例,随机分为对照组和观察组,每组74例。对照组患者给予贝那普利治疗,观察组患者给予瑞舒伐他汀治疗;两组患者均连续治疗3个月。比较两组患者治疗前后运动相关指标(包括等容舒张时间、最大氧摄入量、运动时间及运动最大收缩压)及血浆脑钠肽(BNP)、超敏C反应蛋白(hs-CRP)水平,并观察两组患者治疗期间不良反应发生情况。结果治疗前两组患者等容舒张时间、最大氧摄入量、运动时间及运动最大收缩压比较,差异无统计学意义(P>0.05);治疗后观察组患者等容舒张时间短于对照组,最大氧摄入量高于对照组,运动时间长于对照组,运动最大收缩压低于对照组(P<0.05);治疗后观察组患者等容舒张时间短于治疗前,最大氧摄入量高于治疗前,运动时间长于治疗前,运动最大收缩压低于治疗前(P<0.05);治疗前两组患者血浆BNP、hs-CRP水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血浆BNP、hs-CRP水平低于对照组(P<0.05);治疗后观察组患者血浆BNP、hs-CRP水平低于治疗前(P<0.05)。两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论瑞舒伐他汀可有效降低心脏舒张功能不全并运动高血压患者血浆BNP、hs-CRP水平及运动最大收缩压,改善患者心脏舒张功能,提高患者运动耐量。

Objective To investigate the impact of rosuvastatin on diastolic cardiac dysfunction patients complicated with exercise hypertension. Methods From January 2015 to January 2017,a total of 148 diastolic cardiac dysfunction patients complicated with exercise hypertension were selected in the Department of Cardiovascular Medicine,Gaoming People＇s Hospital of Foshan,and they were randomly divided into control group and observation group,each of 74 cases. Patients of control group received benazepril,while patients of observation group received rosuvastatin; both groups continuously treated for 3 months.Exercise related indicators（ including isovolumic relaxation time,maximum oxygen intake,exercise duration and exercise-induced maximum systolic blood pressure）,plasma levels of BNP and hs-CRP before and after treatment were compared between the two groups, and incidence of adverse reactions was observed during the treatment. Results No statistically significant differences of isovolumic relaxation time,maximum oxygen intake,exercise duration or exercise-induced maximum systolic blood pressure was found between the two groups before treatment（ P〉0. 05）; after treatment,isovolumic relaxation time of observation group was statistically significantly shorter than that of control group,maximum oxygen intake of observation group was statistically significantly higher than that of control group,exercise duration of observation group was statistically significantly longer than that of control group,and exercise-induced maximum systolic blood pressure of observation group was statistically significantly lower than that of control group（ P〈0. 05）. After treatment,isovolumic relaxation time of observation group was statistically significantly shorter than that before treatment, maximum oxygen intake of observation group was statistically significantly higher than that before treatment,exercise duration of observation group was statistically significantly longer than that before treatment,and exercise-induced maximum systolic blood pressure of observation group was statistically significantly lower than that before treatment（ P〈0. 05）. No statistically significant differences of plasma level of BNP or hs-CRP was found between the two groups before treatment（ P〉0. 05）, while plasma levels of BNP and hs-CRP of observation group were statistically significantly lower than those of control group after treatment（ P〈0. 05）. After treatment,plasma levels of BNP and hs-CRP of observation group were statistically significantly lower than those before treatment（ P〈0. 05）. No statistically significant differences of incidence of adverse reactions was found between the two groups during the treatment（ P〉0. 05）.Conclusion Rosuvastatin can effectively reduce the plasma levels of BNP and hs-CRP,and exercise-induced maximum systolic blood pressure of diastolic cardiac dysfunction patients complicated with exercise hypertension, improve the cardiac diastolic function and exercise tolerance.